Epoetin Alfa vs Luspatercept for Myelodysplastic Syndrome

(ELEMENT-MDS Trial)

Recruiting at262 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Recruiting

Sponsor: Bristol-Myers Squibb

Disqualifiers: Secondary MDS, AML, Stroke, others

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing two treatments, Luspatercept and epoetin alfa, to see which is better for treating anemia in adults with certain types of myelodysplastic syndromes (MDS). The participants have not used similar treatments before and do not need regular blood transfusions. Luspatercept helps red blood cells mature, while epoetin alfa increases their production.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, it does mention that participants should not have received more than 2 doses of certain anemia treatments recently.

What data supports the effectiveness of the drug Epoetin Alfa for Myelodysplastic Syndrome?

Epoetin alfa has been used successfully to treat anemia in patients with chronic kidney disease and chemotherapy-related anemia, improving their quality of life by increasing hemoglobin levels. ^{1 2 3 4 5}

How do the drugs Epoetin Alfa and Luspatercept differ from other treatments for myelodysplastic syndrome?

Epoetin Alfa and Luspatercept are unique because they target different pathways to stimulate red blood cell production in patients with myelodysplastic syndrome, a condition where the bone marrow doesn't produce enough healthy blood cells. Epoetin Alfa is a synthetic form of erythropoietin (a hormone that promotes red blood cell production), while Luspatercept works by enhancing the maturation of red blood cells, offering a novel approach compared to traditional treatments. ^{6 7 8 9 10}

Research Team

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Eligibility Criteria

This trial is for adults with Myelodysplastic Syndrome (MDS) who have anemia but don't need blood transfusions. They should not have had previous treatments with erythropoiesis-stimulating agents, and their MDS should be classified as very low to intermediate-risk. Participants must also experience moderate symptoms of fatigue or other related issues due to anemia.

Inclusion Criteria

My average hemoglobin level was 9.5 g/dL or less before joining the study.

Participant has a baseline endogenous serum erythropoietin (sEPO) level of ≤ 500 U/L

Participant is not transfusion dependent (NTD) based on IWG2018 criteria

Exclusion Criteria

My MDS developed after treatment for another disease.

I have been diagnosed with acute myeloid leukemia (AML).

I have had pure red cell aplasia or antibodies against erythropoietin.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Luspatercept or Epoetin Alfa for the treatment of anemia in MDS

96 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Epoetin Alfa (Cancer Treatment)
• Luspatercept (Cancer Treatment)

Trial Overview The study compares Luspatercept against Epoetin Alfa in treating anemia caused by MDS in participants who haven't used similar drugs before. It aims to see which drug is more effective and safer for patients who aren't dependent on blood transfusions.

Participant Groups

Group I: Luspatercept Experimental Treatment 1 Intervention

Group II: Epoetin Alfa Active Control 1 Intervention

Epoetin Alfa is already approved in Canada for the following indications:

Approved in Canada as Eprex for:

• Anemia associated with chronic kidney disease
• Anemia in patients with cancer on chemotherapy
• Anemia in HIV-infected patients

Who Is Running the Clinical Trial?

Bristol-Myers Squibb

Lead Sponsor

Trials

2,731

Recruited

4,127,000+

Headquarters

New York City, USA

Known For

Oncology & Cardiovascular

Top Products

Eliquis, Opdivo, Revlimid, Orencia

Christopher Boerner

Bristol-Myers Squibb

Chief Executive Officer since 2023

PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis

Deepak L. Bhatt

Bristol-Myers Squibb

Chief Medical Officer since 2024

MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania

Findings from Research

Eprex, which contains epoetin alfa, has been successfully marketed in France under the name Binocrit, indicating its availability as a treatment option.

This development suggests that Binocrit may provide similar therapeutic benefits as Eprex, potentially improving patient access to this important medication.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Epoetin alfa: biosimilar. Copied, with biosimilar status. [2015]

Anaemia is a common issue in cancer patients that can negatively impact their quality of life and life expectancy, making effective treatment important.

Epoetin alfa and darbepoetin alfa are promising alternatives to blood transfusions for managing anaemia in cancer patients, as they have been effective in treating anaemia in patients with chronic renal failure.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Epoetins and [symbol: see text] darbepoetin alfa in malignant disease. [2015]

In a study of over 1,500 patients with chronic kidney disease receiving epoetin alfa, only one patient tested low-positive for anti-EPO antibodies, indicating a very low prevalence of these antibodies in this population.

The findings suggest that a large-scale screening program for anti-EPO antibodies in patients treated with epoetin alfa is not necessary, as the risk of developing pure red cell aplasia (PRCA) appears to be minimal.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers. Wu, G., Wadgymar, A., Wong, G., et al.[2019]

Intravitreal aflibercept has emerged as an effective treatment for diabetic macular edema (DME), showing significant improvements in visual acuity in several randomized controlled trials.

Aflibercept's unique mechanism, which includes binding to placental growth factors in addition to VEGF, may provide advantages over other anti-VEGF agents, potentially leading to better outcomes for patients with DME.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Intravitreal Aflibercept in Diabetic Macular Edema: Long-Term Outcomes. Introini, U., Casalino, G.[2017]

Exenatide long-acting release (ELAR) does not increase the risk of cardiovascular events in patients with type 2 diabetes, showing a pooled rate ratio of 0.99 compared to placebo or active comparators based on 16 trials.

ELAR is associated with a significant reduction in all-cause mortality, with a rate ratio of 0.87, suggesting it may be a safer option for patients with type 2 diabetes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Bonora, BM., Avogaro, A., Fadini, GP.[2019]

In a study of 402 patients with diabetic macular edema treated with intravitreal aflibercept (IVT-AFL) over 24 months, treatment-naïve patients showed a significant improvement in best-corrected visual acuity (BCVA) with an average gain of +6.5 letters, indicating the efficacy of IVT-AFL in this group.

Previously treated patients maintained their visual acuity gains, showing that IVT-AFL is effective in preserving vision in those who have already received treatment, with an average of 11.3 to 11.9 injections over the study period.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema. Korobelnik, JF., Daien, V., Faure, C., et al.[2022]

References

1. France pubmed.ncbi.nlm.nih.gov

Epoetin alfa: biosimilar. Copied, with biosimilar status. [2015]

2. United States pubmed.ncbi.nlm.nih.gov

Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. [2023]

3. England pubmed.ncbi.nlm.nih.gov

Epoetins and [symbol: see text] darbepoetin alfa in malignant disease. [2015]

4. England pubmed.ncbi.nlm.nih.gov

Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. [2015]

5. United States pubmed.ncbi.nlm.nih.gov

A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers. [2019]

6. England pubmed.ncbi.nlm.nih.gov

European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. [2021]

7. United States pubmed.ncbi.nlm.nih.gov

Safety and Efficacy of Ziv-Aflibercept in the Treatment of Refractory Diabetic Macular Edema. [2022]

8. Switzerland pubmed.ncbi.nlm.nih.gov

Intravitreal Aflibercept in Diabetic Macular Edema: Long-Term Outcomes. [2017]

9. Germany pubmed.ncbi.nlm.nih.gov

Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. [2019]

10. England pubmed.ncbi.nlm.nih.gov

Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema. [2022]